Stephen Speicher, Will Shapiro, Taylor Dias-Foundas
This report explores the transformative impact of artificial intelligence (AI) in health care, emphasizing its potential paradigm shift and current deployment in oncology.
{"title":"Shifting the Paradigm: The Impact of AI at the Point of Care in Cancer Treatment","authors":"Stephen Speicher, Will Shapiro, Taylor Dias-Foundas","doi":"10.25270/jcp.2024.05.03","DOIUrl":"https://doi.org/10.25270/jcp.2024.05.03","url":null,"abstract":"This report explores the transformative impact of artificial intelligence (AI) in health care, emphasizing its potential paradigm shift and current deployment in oncology.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141277093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sabree C Burbage, Dexter Waters, C. Rossi, F. Kinkead, Erik Muser, L. Ellis, Patrick Lefebvre, D. Pilon
This retrospective study used electronic medical record data from community-based urology practices in the US (February 1, 2017, to September 17, 2021) to describe prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs) with or without in-office dispensing (IOD) services. Patients who were prescribed apalutamide, darolutamide, or enzalutamide were classified in IOD+ (IOD access + fill), IOD– (IOD access + no fill), or non-IOD cohorts (no IOD access). Outcomes were described by cohort from 14 days following initial prescription to the earliest of initiation of a new ARI or advanced prostate cancer medication, end of clinical activity, or end of data availability. In total, 3300 patients were included (IOD+: n = 615; IOD–: n = 2474; non-IOD: n = 211). PSA response defined as a decline ≥50% from the baseline PSA value (PSA50) achieved by 6 and 12 months was observed in 80.0% and 83.8% of patients in the IOD+ cohort, 63.8% and 72.3% in the IOD– cohort, and 62.5% and 69.1% in the non-IOD cohort. Patients in the IOD+ cohort underwent fewer bone scans, computerized tomography, and next-generation imaging than IOD– and non-IOD cohorts and also had longer time from treatment initiation to first follow-up imaging. IOD services may better support comprehensive disease management for patients with nmCRPC receiving next-generation ARIs and may be associated with better long-term clinical outcomes.
{"title":"PSA Outcomes and Clinical Surveillance Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With a Next-Generation Androgen Receptor Inhibitor in Urology Practices With or Without In-Office Dispensing","authors":"Sabree C Burbage, Dexter Waters, C. Rossi, F. Kinkead, Erik Muser, L. Ellis, Patrick Lefebvre, D. Pilon","doi":"10.25270/jcp.2024.05.01","DOIUrl":"https://doi.org/10.25270/jcp.2024.05.01","url":null,"abstract":"This retrospective study used electronic medical record data from community-based urology practices in the US (February 1, 2017, to September 17, 2021) to describe prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs) with or without in-office dispensing (IOD) services. Patients who were prescribed apalutamide, darolutamide, or enzalutamide were classified in IOD+ (IOD access + fill), IOD– (IOD access + no fill), or non-IOD cohorts (no IOD access). Outcomes were described by cohort from 14 days following initial prescription to the earliest of initiation of a new ARI or advanced prostate cancer medication, end of clinical activity, or end of data availability. In total, 3300 patients were included (IOD+: n = 615; IOD–: n = 2474; non-IOD: n = 211). PSA response defined as a decline ≥50% from the baseline PSA value (PSA50) achieved by 6 and 12 months was observed in 80.0% and 83.8% of patients in the IOD+ cohort, 63.8% and 72.3% in the IOD– cohort, and 62.5% and 69.1% in the non-IOD cohort. Patients in the IOD+ cohort underwent fewer bone scans, computerized tomography, and next-generation imaging than IOD– and non-IOD cohorts and also had longer time from treatment initiation to first follow-up imaging. IOD services may better support comprehensive disease management for patients with nmCRPC receiving next-generation ARIs and may be associated with better long-term clinical outcomes.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141275459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrew L Pecora, Lili Brillstein, M. Albitar, Nasim Asfar, Joel Brill, Jeffrey R. Curtis, Andrew von Eschenbach, Deborah Goss, Andre Goy, Max Holfert, Andrew Ip, Allen Karp, Mark Lutes, Steven Madreperla, Patrick A. Roth, Miruna Sasu, Robert Shelley, Robin L. Smith, Nina Tandon, Dan Varga, Richard Winters
Health care in the US remains challenged by affordability, availability, and wasteful spending. To address these challenges, the various constituents in health care payment and delivery all seek to reduce total cost of care while maintaining or improving the relevant clinical outcome expected (value-based care). It is generally acknowledged that health care is not one system but is, in fact, fragmented in control and delivery between local and national commercial payers, government payers, employers, private and public providers, and drug and device manufacturers, all of whom are overseen by state and federal regulations. To help guide further discussion on current and evolving value-based care strategies, this paper provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US.
{"title":"Bringing Value to Health Care","authors":"Andrew L Pecora, Lili Brillstein, M. Albitar, Nasim Asfar, Joel Brill, Jeffrey R. Curtis, Andrew von Eschenbach, Deborah Goss, Andre Goy, Max Holfert, Andrew Ip, Allen Karp, Mark Lutes, Steven Madreperla, Patrick A. Roth, Miruna Sasu, Robert Shelley, Robin L. Smith, Nina Tandon, Dan Varga, Richard Winters","doi":"10.25270/jcp.2024.05.02","DOIUrl":"https://doi.org/10.25270/jcp.2024.05.02","url":null,"abstract":"Health care in the US remains challenged by affordability, availability, and wasteful spending. To address these challenges, the various constituents in health care payment and delivery all seek to reduce total cost of care while maintaining or improving the relevant clinical outcome expected (value-based care). It is generally acknowledged that health care is not one system but is, in fact, fragmented in control and delivery between local and national commercial payers, government payers, employers, private and public providers, and drug and device manufacturers, all of whom are overseen by state and federal regulations. To help guide further discussion on current and evolving value-based care strategies, this paper provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141280010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Hayes, A. V. Van Citters, Wenyan Zhao, Kate L. Caldon, Charlotte M. Coughenour, T. Tosteson, Anna N. A. Tosteson, Kenneth R. Meehan
Background: Patient-reported outcome measures (PROMs) offer a collaborative opportunity between the patient and the care team to improve the quality of care. Objectives: To define PROMs in patients receiving hematopoietic stem cell transplant (HSCT), a pre-visit questionnaire (PVQ) was developed, which included a single agenda-setting question, the PROMIS-29 survey, and the National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT). Study Design: Patients completed the PVQ 1 month prior to transplant (baseline) and at 1, 3, 6, and 12 months following transplant. Results: Sixty-five patients (n = 27 allogenic; n = 38 autologous) participated. Survey completion rates were 95% at 1 month post-transplant, 74% at 6 months, and 65% at one year. One month following transplant, patients’ fatigue (P < .001) increased, while physical (P < .001) and social (P < .001) functions decreased. Each returned to baseline at 3 months (P < .001). Fatigue was more pronounced in allogeneic recipients (P = .017) and autologous recipients recovered physical function much sooner (P = .021). Conclusions: This study confirms the feasibility of capturing PROMs longitudinally in patients receiving HSCT and demonstrates significant changes in fatigue and physical and social functioning following transplant.
{"title":"Patient-Reported Outcomes in Hematopoietic Stem Cell Transplant Recipients: Design, Implementation, and Pilot Results","authors":"C. Hayes, A. V. Van Citters, Wenyan Zhao, Kate L. Caldon, Charlotte M. Coughenour, T. Tosteson, Anna N. A. Tosteson, Kenneth R. Meehan","doi":"10.25270/jcp.2024.03.02","DOIUrl":"https://doi.org/10.25270/jcp.2024.03.02","url":null,"abstract":"Background: Patient-reported outcome measures (PROMs) offer a collaborative opportunity between the patient and the care team to improve the quality of care. Objectives: To define PROMs in patients receiving hematopoietic stem cell transplant (HSCT), a pre-visit questionnaire (PVQ) was developed, which included a single agenda-setting question, the PROMIS-29 survey, and the National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT). Study Design: Patients completed the PVQ 1 month prior to transplant (baseline) and at 1, 3, 6, and 12 months following transplant. Results: Sixty-five patients (n = 27 allogenic; n = 38 autologous) participated. Survey completion rates were 95% at 1 month post-transplant, 74% at 6 months, and 65% at one year. One month following transplant, patients’ fatigue (P < .001) increased, while physical (P < .001) and social (P < .001) functions decreased. Each returned to baseline at 3 months (P < .001). Fatigue was more pronounced in allogeneic recipients (P = .017) and autologous recipients recovered physical function much sooner (P = .021). Conclusions: This study confirms the feasibility of capturing PROMs longitudinally in patients receiving HSCT and demonstrates significant changes in fatigue and physical and social functioning following transplant.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140356990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Previs, Maureen E. Cooper, Kyle C. Strickland, Heidi Ko, Michelle F. Green, F. Koohestani, S. Hastings, Zachary D. Wallen, S. Pabla, Jeffrey M. Conroy, M. Nesline, Shengle Zhang, Durga Prasad Dash, Brian J. Caveney, Marcia Eisenberg, Eric A Severson, Shakti H. Ramkissoon
Biomarker-driven targeted therapies have shaped the oncology treatment landscape for patients with advanced solid tumors over the past decade. Comprehensive genomic profiling (CGP) has played a key role in precision medicine as it enables simultaneous identification of multiple biomarkers to guide cancer diagnosis, therapy selection, and prognostication. As a result, tissue stewardship for successful CGP testing is paramount. In addition, widespread adoption of less invasive sampling techniques leaves less diagnostic tissue for additional or future testing as smaller biopsies are acquired. To help oncology care practitioners overcome these challenges, this paper provides an overview of current genomic testing methodologies and offers guidelines on best practices for tissue stewardship and preanalytic practices for successful CGP testing and efficient turnaround times for laboratory tests.
{"title":"Comprehensive Genomic Testing: Tissue Stewardship and Best Practices","authors":"R. Previs, Maureen E. Cooper, Kyle C. Strickland, Heidi Ko, Michelle F. Green, F. Koohestani, S. Hastings, Zachary D. Wallen, S. Pabla, Jeffrey M. Conroy, M. Nesline, Shengle Zhang, Durga Prasad Dash, Brian J. Caveney, Marcia Eisenberg, Eric A Severson, Shakti H. Ramkissoon","doi":"10.25270/jcp.2024.03.01","DOIUrl":"https://doi.org/10.25270/jcp.2024.03.01","url":null,"abstract":"Biomarker-driven targeted therapies have shaped the oncology treatment landscape for patients with advanced solid tumors over the past decade. Comprehensive genomic profiling (CGP) has played a key role in precision medicine as it enables simultaneous identification of multiple biomarkers to guide cancer diagnosis, therapy selection, and prognostication. As a result, tissue stewardship for successful CGP testing is paramount. In addition, widespread adoption of less invasive sampling techniques leaves less diagnostic tissue for additional or future testing as smaller biopsies are acquired. To help oncology care practitioners overcome these challenges, this paper provides an overview of current genomic testing methodologies and offers guidelines on best practices for tissue stewardship and preanalytic practices for successful CGP testing and efficient turnaround times for laboratory tests.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140354115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study investigates the challenges leading to a substantial decline in participation among academic oncology practices within the Enhancing Oncology Model (EOM), introduced as a successor to the Oncology Care Model (OCM) by the CMS Innovation Center. Analyzing the withdrawal of 14 practices from the EOM, previously part of the OCM Collaborative, three primary factors are identified: immediate downside risk in a context of narrow provider margins, inadequate risk adjustment failing to appropriately account for drug costs, and onerous reporting burdens for extensive clinical data. Under the EOM, immediate downside risk for seven specified cancers diverged significantly from the OCM’s upside-only risk structure, posing financial challenges for practices. Inadequate risk adjustment, particularly the omission of crucial clinical data, raised concerns about the model’s focus on drug costs without considering essential patient-specific variables. The study also highlights the burden of reporting requirements, exacerbated by reduced enhanced services payments, impacting practices financially. To address these challenges and encourage EOM participation, policy options are proposed. These include reconsidering financial risk levels, refining target price methodology to incorporate clinical data, and reducing reporting burdens by aligning data requirements with EOM financial and quality methodologies. These adjustments aim to strengthen the EOM, fostering more accurate performance measurement and incentivizing high-quality patient care delivery in oncology practices.
{"title":"The Key Factors Driving Low Participation in the Enhancing Oncology Model","authors":"Theresa Dreyer","doi":"10.25270/jcp.2024.01.01","DOIUrl":"https://doi.org/10.25270/jcp.2024.01.01","url":null,"abstract":"This study investigates the challenges leading to a substantial decline in participation among academic oncology practices within the Enhancing Oncology Model (EOM), introduced as a successor to the Oncology Care Model (OCM) by the CMS Innovation Center. Analyzing the withdrawal of 14 practices from the EOM, previously part of the OCM Collaborative, three primary factors are identified: immediate downside risk in a context of narrow provider margins, inadequate risk adjustment failing to appropriately account for drug costs, and onerous reporting burdens for extensive clinical data. Under the EOM, immediate downside risk for seven specified cancers diverged significantly from the OCM’s upside-only risk structure, posing financial challenges for practices. Inadequate risk adjustment, particularly the omission of crucial clinical data, raised concerns about the model’s focus on drug costs without considering essential patient-specific variables. The study also highlights the burden of reporting requirements, exacerbated by reduced enhanced services payments, impacting practices financially. To address these challenges and encourage EOM participation, policy options are proposed. These include reconsidering financial risk levels, refining target price methodology to incorporate clinical data, and reducing reporting burdens by aligning data requirements with EOM financial and quality methodologies. These adjustments aim to strengthen the EOM, fostering more accurate performance measurement and incentivizing high-quality patient care delivery in oncology practices.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139966393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Poka Cui, Peter Blanshard, María Teresa Campos-Partera, A. Moucquot, S. H. R. Naqvi, D. Dellamonica, Heather Moses
Multidisciplinary teams (MDTs) play a pivotal role in the comprehensive management of cancer. MDT meetings (MDTMs) bring together specialized experts across the entire patient care spectrum, convening regularly to discuss patient cases, select optimal diagnostic strategies, and determine the most appropriate treatment modalities. By fostering cross-disciplinary interaction, MDTs aim to enhance patient outcomes and elevate the collective proficiency within a health care institution, promoting knowledge dissemination and ensuring health care practitioners remain abreast of the latest clinical insights. This study’s methods comprised an extensive review of existing literature coupled with interviews involving lung cancer MDTs from 24 medical centers across Europe and Canada. The research focused on elucidating dynamics and variations observed among lung cancer MDTs, outlining an optimal MDT process, identifying variances in the study sample, and introducing a comprehensive self-assessment toolkit for continuous evaluation and improvement. The report discusses how these results should be used to self-optimize hospital MDTs, promote standardization, and encourage increased cross-hospital best practices sharing. With this, MDTs will be better positioned to deliver on the key goal of improved patient outcomes while promoting equality of access to health care.
{"title":"Enhancing Multidisciplinary Team Processes in Lung Cancer Care: A Self-Assessment Toolkit and Best Practices","authors":"Poka Cui, Peter Blanshard, María Teresa Campos-Partera, A. Moucquot, S. H. R. Naqvi, D. Dellamonica, Heather Moses","doi":"10.25270/jcp.2024.01.02","DOIUrl":"https://doi.org/10.25270/jcp.2024.01.02","url":null,"abstract":"Multidisciplinary teams (MDTs) play a pivotal role in the comprehensive management of cancer. MDT meetings (MDTMs) bring together specialized experts across the entire patient care spectrum, convening regularly to discuss patient cases, select optimal diagnostic strategies, and determine the most appropriate treatment modalities. By fostering cross-disciplinary interaction, MDTs aim to enhance patient outcomes and elevate the collective proficiency within a health care institution, promoting knowledge dissemination and ensuring health care practitioners remain abreast of the latest clinical insights. This study’s methods comprised an extensive review of existing literature coupled with interviews involving lung cancer MDTs from 24 medical centers across Europe and Canada. The research focused on elucidating dynamics and variations observed among lung cancer MDTs, outlining an optimal MDT process, identifying variances in the study sample, and introducing a comprehensive self-assessment toolkit for continuous evaluation and improvement. The report discusses how these results should be used to self-optimize hospital MDTs, promote standardization, and encourage increased cross-hospital best practices sharing. With this, MDTs will be better positioned to deliver on the key goal of improved patient outcomes while promoting equality of access to health care.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139966600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Freedland, Imtiaz Samjoo, Emily Rosta, A. Lansing, Alexandra Hall, Manvir Rai, A. Niyazov, J. Nazari, B. Arondekar
A systematic literature review by Stephen J. Freedland, MD, and colleagues summarizes the current evidence relating to social determinants of health beyond race and survival in patients with metastatic prostate cancer.
Stephen J. Freedland 医学博士及其同事撰写了一篇系统性文献综述，总结了目前与种族以外的健康社会决定因素和转移性前列腺癌患者存活率有关的证据。
{"title":"The Impact of Social Determinants of Health Beyond Race on Survival in Metastatic Prostate Cancer: A Systematic Literature Review","authors":"S. Freedland, Imtiaz Samjoo, Emily Rosta, A. Lansing, Alexandra Hall, Manvir Rai, A. Niyazov, J. Nazari, B. Arondekar","doi":"10.25270/jcp.2023.11.01","DOIUrl":"https://doi.org/10.25270/jcp.2023.11.01","url":null,"abstract":"A systematic literature review by Stephen J. Freedland, MD, and colleagues summarizes the current evidence relating to social determinants of health beyond race and survival in patients with metastatic prostate cancer.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139192415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Simon Davies, Kathleen Lyons, Kausik Mukherjee, Ramakrishna Kishore, Khurram Hashmi, Maria Dyban, Anna Kuczynska
Simon R. Davies, MBBCh, and colleagues investigate the impact of HealthPathways on management and primary care clinicians in a musculoskeletal radiology department.
MBBCh Simon R. Davies 及其同事调查了 HealthPathways 对肌肉骨骼放射科管理和初级保健临床医生的影响。
{"title":"Clinical and Economic Impact of Implementing HealthPathways at a Musculoskeletal Radiology Department","authors":"Simon Davies, Kathleen Lyons, Kausik Mukherjee, Ramakrishna Kishore, Khurram Hashmi, Maria Dyban, Anna Kuczynska","doi":"10.25270/jcp.2023.11.02","DOIUrl":"https://doi.org/10.25270/jcp.2023.11.02","url":null,"abstract":"Simon R. Davies, MBBCh, and colleagues investigate the impact of HealthPathways on management and primary care clinicians in a musculoskeletal radiology department.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139196426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：